Unassociated Document


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION 
Washington, D.C. 20549
 

FORM 8-K

 
CURRENT REPORT

Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 21, 2009

 
ORAMED PHARMACEUTICALS INC.
(Exact name of registrant as specified in its charter)
 
Nevada
(State or other jurisdiction
of incorporation)
000-50298
(Commission File Number)
98-0376008
(IRS Employer
Identification No.)

Hi-Tech Park 2/5 Givat Ram
PO Box 39098
Jerusalem, Israel 91390
 (Address of principal executive offices and zip code)

Registrant’s telephone number, including area code: 972-2-566-0001
 

 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
 
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) 

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) 

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) 

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) 
 


 
 

 
 
ITEM 7.01
REGULATION FD DISCLOSURE

On October 20, 2009, Oramed Pharmaceuticals Inc. issued a press release announcing that its poster entitled “A novel GLP-1 analog delivered orally reduces postprandial glucose excursions in a porcine model,” has been accepted for presentation at the Diabetes Technology Society’s Ninth Annual Meeting in San Francisco, California between November 5-7, 2009.
 
A copy of the press release is attached to this Current Report on Form 8-K as Exhibit 99.1 and is incorporated by reference herein.

ITEM 9.01
FINANCIAL STATEMENTS AND EXHIBITS.

(d)
Exhibits

Exhibit Number
 
Description
 
       
99.1
 
Press Release dated October 20, 2009.
 
 
 
 

 
 
SIGNATURES
 
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
 
ORAMED PHARMACEUTICALS INC. 
 
Dated: October 21, 2009
     
 
By:
/s/ Nadav Kidron 
 
   
Nadav Kidron 
 
   
President, CEO and Director 
 
 
 
 

 
 
Exhibit Index

Exhibit Number
 
Description
     
99.1
 
Press Release dated October 20, 2009.

 
 
 

 
Unassociated Document
 
 
 
Oramed Pharmaceuticals was Chosen to Present Results of a GLP-1
Analog Oral Administration Study at the Diabetes Technology Society’s
Ninth Annual Meeting (November 5-7, 2008; San Francisco, California)
 
 
JERUSALEM, Israel – October 20, 2009 – Oramed Pharmaceuticals, Inc. (OTCBB: ORMP.OB; www.oramed.com), a developer of oral drug delivery systems, announced today that its poster entitled “A novel GLP-1 analog delivered orally reduces postprandial glucose excursions in a porcine model,” has been accepted for presentation at the Diabetes Technology Society’s Ninth Annual Meeting in San Francisco, California between November 5-7, 2009.

“The selection of Oramed as one of the companies to present at the Diabetes Technology Conference is a wonderful opportunity for us to demonstrate our technology to the world’s leading diabetes scientists,” said Nadav Kidron, Oramed CEO.

Oramed’s abstract will be presented on Thursday November 5, 2009, at 5:30 PM. The poster will be available for viewing throughout the conference.

For more information about the Diabetes Technology Society’s Ninth Annual Meeting, please visit http://www.diabetestechnology.org/

For more information about Oramed Pharmaceuticals, please visit www.oramed.com
 
 
About Oramed Pharmaceuticals
 
Oramed Pharmaceuticals is a technology pioneer in the field of oral delivery solutions for drugs and vaccines presently delivered via injection.  Oramed is seeking to revolutionize the treatment of diabetes through its patented flagship product, an orally ingestible insulin capsule currently in phase 2 clinical trials. Established in 2006, Oramed’s technology is based on over 25 years of research by top research scientists at Jerusalem’s Hadassah Medical Center. The Company’s corporate and R&D headquarters are based in Jerusalem.
 
For more information, please visit www.oramed.com 
 
 
 

 
 
Forward-looking statements
 
Some of the statements contained in this press release are forward-looking statements which involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the company, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward looking statements, including the risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval for our product candidates; competition from other pharmaceutical or biotechnology companies; and the company’s ability to obtain additional funding required to conduct its research, development and commercialization activities. Please refer to the company’s filings with the Securities and Exchange Commission for a comprehensive list of risk factors that could cause actual results, performance or achievements of the company to differ materially from those expressed or implied in such forward looking statements. The company undertakes no obligation to update or revise any forward-looking statements. 
 
Company Contact:
Oramed Pharmaceuticals
Tara Horn
Cell: + 972-54-334-318
Office: + 972-2-566-0001
Email: tara@oramed.com